文献速递类风湿关节炎其他结缔组织病

自身免疫炎症性风湿病患者接种BNT162b2 mRNA疫苗后带状疱疹病例系列

Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该观察性研究在以色列两个风湿科监测自身免疫炎症性风湿病(AIIRD)患者接种BNT162b2 mRNA疫苗后的不良反应,AIIRD患者491例、对照99例。AIIRD患者带状疱疹患病率为1.2%(6例),对照中无病例;6例均为病情稳定的女性,多数症状轻微,1例为接受托法替布治疗的RA患者发生无角膜受累的眼部带状疱疹。

要点

  • AIIRD患者接种BNT162b2后带状疱疹患病率1.2%,对照为0,需警惕但属少见事件。
  • 6例带状疱疹均为女性、病情稳定,5例发生于第一剂后、1例发生于第二剂后。
  • 多数症状轻微,无播散性带状疱疹及带状疱疹后神经痛,抗病毒治疗后缓解。

核心结论

  • AIIRD患者接种BNT162b2 mRNA疫苗后出现带状疱疹再激活的少数病例,症状多轻微,但二者关联需流行病学研究澄清。

研究设计与样本

  • 以色列两个风湿科开展的观察性研究,监测接种后不良反应,AIIRD患者491例、对照99例。

主要发现

  • AIIRD患者带状疱疹患病率为1.2%(6例),对照中无带状疱疹病例。
  • 6例均为女性,年龄49±11岁,病情稳定:RA 4例、干燥综合征1例、未分化结缔组织病1例。
  • 5例带状疱疹发生于第一剂疫苗后不久,1例发生于第二剂后;多数轻微,1例RA患者(接受托法替布)发生无角膜受累的眼部带状疱疹。
  • 无播散性带状疱疹及带状疱疹后神经痛病例;除1例外均接受抗病毒治疗,带状疱疹相关症状至多6周缓解。
  • 5例完成第二剂接种且无其他不良反应。

临床怎么用

  • 对病情稳定的AIIRD患者接种BNT162b2后应关注带状疱疹再激活,出现皮疹及时识别并抗病毒治疗。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: As global vaccination campaigns against COVID-19 disease commence, vaccine safety needs to be closely assessed. The safety profile of mRNA-based vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) is unknown. The objective of this report is to raise awareness of reactivation of herpes zoster (HZ) following the BNT162b2 mRNA vaccination in patients with AIIRD. METHODS: The safety of the BNT162b2 mRNA vaccination was assessed in an observational study monitoring post-vaccination adverse effects in patients with AIIRD (n = 491) and controls (n = 99), conducted in two rheumatology departments in Israel. RESULTS: The prevalence of HZ was 1.2% (n = 6) in patients with AIIRD compared with none in controls. Six female patients aged 49 ± 11 years with stable AIIRD: RA (n = 4), Sjogren's syndrome (n = 1), and undifferentiated connective disease (n = 1), developed the first in a lifetime event of HZ within a short time after the first vaccine dose in five cases and after the second vaccine dose in one case. In the majority of cases, HZ infection was mild, except a case of HZ ophthalmicus, without corneal involvement, in an RA patient treated with tofacitinib. There were no cases of disseminated HZ disease or postherpetic neuralgia. All but one patient received antiviral treatment with a resolution of HZ-related symptoms up to 6 weeks. Five patients completed the second vaccine dose without other adverse effects. CONCLUSION: Epidemiologic studies on the safety of the mRNA-based COVID-19 vaccines in patients with AIIRD are needed to clarify the association between the BNT162b2 mRNA vaccination and reactivation of zoster.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Furer V, Zisman D, Kibari A, et al. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford). 2021. PMID: 33848321. doi:10.1093/rheumatology/keab345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。